Daix (France), Long Island City (New York, USA), January 3, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) focused on developing oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other critical unmet medical needs announced today that it is a clinical-stage biopharmaceutical company. Availability of preparatory documents for the Consolidated Assembly on 25 January 2023.
Shareholders are invited to attend the Joint General Meeting of Shareholders to be held on January 25, 2023 at 2:00 pm at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon (France).
Advance notice of the meeting, including the agenda and resolutions, and information on how to attend and vote at the Joint General Assembly, is available at Bulletin des Annonces Légales Obligatoires (BALO) No. 151 of December 19, 2022, translation filed with the Securities and Exchange Commission on December 19, 2022.
Information and documents relating to the Joint Shareholders’ Meeting are available on our website (www.inventivapharma.com, section “Investors”/”Shareholders’ Meeting”).
Pursuant to articles R. 225-83 and R. 225-89 of the French Commercial Code, the documents that the shareholders need to have available for the shareholders’ meeting shall be sent to the Company’s registered office (50, Rue de Dijon, 21121 Daix, of the Consolidated General Meeting). 15 days ago.
The documents referred to in Article R.22-10-23 of the French Commercial Code will be available as of tomorrow, 21 days before the General Assembly, on the above-mentioned Inventiva website.
In accordance with applicable regulatory provisions:
Shareholders holding registered shares may request that these documents be sent to the Company at least five days prior to the General Meeting of Shareholders. For shareholders who hold bearer shares, exercising this right requires submission of a certificate of shareholding issued by the financial intermediary.
Shareholders may consult these documents at our registered office by sending an email request to the following electronic address: AGIVA25012023@inventivapharma.com.
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small-molecule therapies for the treatment of patients with critical unmet medical needs, including NASH and mucopolysaccharidosis (MPS). We benefit from strong expertise and experience in the domains of compounds targeting nuclear receptors, transcription factors and epigenetic regulation. Inventiva currently has one clinical candidate underway, has a pipeline of two preclinical programs, and continues to explore other development opportunities to add to its pipeline.
Inventiva’s lead product candidate, ranifibranol, is in an pivotal Phase 3 clinical trial for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there is currently no approved therapy. There is NATiV3 in progress. In 2020, Inventiva reports positive results from a Phase 2b clinical trial evaluating lanifibranol for the treatment of NASH patients, breaking the U.S. Food and Drug Administration (“FDA”) for lanifibranol in the treatment of NASH Received Through Therapy and Fast Track status.
Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus its clinical efforts on the development of ranifibranol, the company has suspended clinical efforts related to his odiparcil and is reviewing available options for potential future development. increase. Inventiva is selecting oncology development candidates for its Hippo signaling pathway program.
We have a scientific team of approximately 80 people with deep expertise in the areas of biology, medical and computational chemistry, pharmacokinetics and pharmacology, and clinical development. The company owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
Inventiva is a public company listed on the Euronext Paris regulated market compartment C (ticker: IVA – ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.
This press release contains “forward-looking statements” within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements include, but are not limited to, Inventiva’s pipeline, preclinical and clinical development plans, future activities, expectations, plans, growth and prospects for Inventiva and its product candidates. Some of these statements, projections and estimates use words such as “believe,” “predict,” “expect,” “intend,” “plan,” “seek,” “estimate,” and the like. It can be recognized by using, but not limited to: “may”, “will”, “would”, “could”, “may”, “should”, “continue” and similar expressions. Such statements are not historical facts, but rather forward-looking statements based on management’s beliefs and other forward-looking statements. These statements reflect views and assumptions as of the date they are made and may cause future results, performance or future events to differ materially from those expressed or implied by such statements. It involves known and unknown risks and uncertainties. Future events are difficult to predict and may be dependent on factors beyond Inventiva’s control. For pipeline product candidates, there is no assurance that clinical trial results will be available in the anticipated timelines, future clinical trials will commence as expected, or that product candidates will receive the necessary regulatory approvals. is not. The actual result is that Inventiva is a clinical-stage company with no approved products, and that Inventiva has suffered significant losses since its inception. Never generated revenue from sales Inventiva needs additional capital to fund its operations Inventiva’s future success depends on successful clinical development Regulators of current and future product candidates approval and subsequent commercialization, preclinical or early clinical trials are not necessarily predictive of future results, and the results of Inventiva’s clinical trials may not support claims made by Inventiva’s product candidates, and Inventiva’s may encounter significant delays in its clinical trials. Inventiva may also be unable to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. Enrolling and maintaining patients in clinical trials is an expensive and time-consuming process that may be made more difficult or impossible by several factors outside of Inventiva’s control, including Inventiva’s products. Inventiva faces substantial competition, which affects Inventiva’s business, preclinical studies, clinical development programs and timelines, financial condition and results of operations, disputes between Russia and Ukraine, related sanctions, related impacts, and expected timescales. It could be materially and adversely affected by the current COVID-19 pandemic and geopolitical events, including the potential impact on the initiation, enrollment and completion of Inventiva’s clinical trials on the line. Macroeconomic conditions, including global inflation and uncertain financial markets, or at all. Given these risks and uncertainties, no representation is made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. In addition, forward-looking statements, forecasts and estimates speak only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements.
Universal Registration Document for the year ended 31 December 2021 filed with the Autorité des Marchés Financiers on 11 March 2022, Form 20 for the year ended 31 December 2021 filed with the Stock Exchange See -F annual report. The Commission on March 11, 2022 and the financial report for the first half of 2022 will be filed with the Securities and Exchange Commission on September 22, 2022 to request additional information regarding such factors, risks and uncertainties. I was.
All information in this press release is current as of the date of release. Except as required by law, Inventiva does not intend and undertakes no obligation to update or confirm the forward-looking statements set forth above.